Delanzomib

Delanzomib(CEP-18770)是口服活性的蛋白酶体糜蛋白酶样活性抑制剂,能下调核内NF-kappaB活性。

信号通路 >> 代谢酶/蛋白酶 >> 蛋白酶体

研究领域 >> 癌症

[1]. Piva R, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008 Mar 1;111(5):2765-75.

[2]. Sanchez E, et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol. 2010 Feb;148(4):569-81.

[3]. Seavey MM, et al. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70.

[4]. Gallerani E, et al. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer. 2013 Jan;49(2):290-6.

蛋白酶体抑制剂 | 雷公藤红素; 南蛇藤素 | ONX-0914 | 胃蛋白酶抑制剂 | 环氧酶素 | 艾沙佐米 | 钙蛋白酶抑制剂I | Oprozomib (ONX 0912) | PD150606 | RA190 | Capzimin | 甲磺酸加贝酯 | PI-1840 | VR23 | PD 151746